How are energy investors positioned?
SOUTH JORDAN, UT—Fred Lampropoulos, President and CEO of Merit Medical Systems Inc. (NASDAQ:MMSI), recently sold 20,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $96.54, generating approximately $1.93 million in proceeds. The transaction comes as Merit Medical (TASE:BLWV), with a market capitalization of $5.6 billion, maintains a "GREAT" financial health score according to InvestingPro analysis.
Following the transaction, Lampropoulos retains ownership of 1,066,028 shares directly. Additionally, he holds indirect ownership through various accounts, including shares held by his spouse and through a 401(k) plan.
Merit Medical Systems, headquartered in South Jordan, Utah, specializes in the development and manufacturing of medical devices used in diagnostic and therapeutic procedures. The company has demonstrated solid performance with 8.2% revenue growth in the last twelve months and maintains healthy liquidity with a current ratio of 4.87. The recent stock sale reflects a portion of Lampropoulos’ holdings in the company, with a significant number of shares still under his ownership. InvestingPro analysis indicates the stock is trading above its Fair Value, with 12 additional exclusive insights available to subscribers.
In other recent news, Merit Medical Systems has announced significant developments impacting its business and future outlook. The company recently completed the acquisition of Biolife Delaware L.L.C. for $120 million in cash, which is expected to generate approximately $18 million in annualized revenue starting in fiscal year 2026. Despite an anticipated slight dilution to non-GAAP EPS in 2025, the acquisition is projected to be accretive to non-GAAP margins and earnings per share by 2026. Merit Medical also reaffirmed its full-year 2025 financial guidance, projecting net sales between $1.480 billion and $1.501 billion, with non-GAAP earnings per share estimated at $3.28 to $3.41.
Canaccord Genuity responded to this acquisition by raising its price target for Merit Medical to $112, maintaining a Buy rating. Meanwhile, Needham analysts adjusted their price target to $100 from $116, although they also retained a Buy rating following the company’s first-quarter 2025 earnings report, which exceeded consensus estimates. The firm noted a slight downward revision in EPS guidance due to tariff impacts but highlighted the company’s strong revenue growth and margin improvements.
Additionally, Merit Medical received Health Canada approval for its WRAPSODY CIE device, aimed at improving outcomes for hemodialysis patients. The device demonstrated superior performance in clinical trials and is now commercially available in multiple regions, including Canada, the United States, and the European Union. These developments illustrate Merit Medical’s strategic efforts to expand its product portfolio and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.